Lutetium Lu 177 Dotatate 7.4 GBq/ vial Suppliers & Bulk Manufacturers

Available Forms: Injection

Available Strengths: 7.4 GBq/ vial

Reference Brands: Lutathera (USA, EU)

Category: Oncology Cancer Care

Lutathera is a radiolabeled peptide receptor radionuclide therapy (PRRT) used to treat gastroenteropancreatic neuroendocrine tumors (GEP-NETs) that express somatostatin receptors. It works by delivering targeted radiation directly to tumor cells, minimizing damage to surrounding healthy tissue. The therapy is administered via intravenous infusion under specialized medical supervision, usually in cycles of four doses spaced eight weeks apart.

Product Description:

Lutetium Lu 177 dotatate is a radiopharmaceutical rather than a drug in the ordinary sense. A somatostatin analogue peptide is chemically tethered to a radioactive lutetium-177 atom. The peptide binds somatostatin receptor type 2, which neuroendocrine tumours express in great abundance, and the radionuclide is carried inside the cell where its beta emissions destroy DNA over a range of about two millimetres — long enough to kill neighbouring tumour cells, short enough to spare surrounding tissue.

It is used for somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours, given as four intravenous infusions eight weeks apart, with an amino acid solution co-infused to protect the kidneys from peptide reabsorption. Eligibility is established by receptor imaging beforehand — a tumour that does not take up the tracer will not take up the therapy. Nausea from the amino acid infusion, myelosuppression, and a small long-term risk of myelodysplastic syndrome are the main concerns.

Sourcing notes. This product decays. The half-life is under seven days, so it is manufactured to order against a named patient and a booked infusion slot, shipped in shielded containers under nuclear transport rules, and wasted entirely if the appointment slips. Only licensed nuclear medicine centres can receive it.